1. High-Throughput immunogenetics for precision medicine in cancer
- Author
-
Anton W. Langerak, A. Agathangelidis, Elisavet Vlachonikola, Anastasia Chatzidimitriou, Frederic Davi, and Immunology
- Subjects
Cancer Research ,Computer science ,Immunogenetics ,Computational biology ,Cancer pathogenesis ,SDG 3 - Good Health and Well-being ,Next generation sequencing ,Neoplasms ,Tumor Microenvironment ,medicine ,Humans ,Precision Medicine ,Throughput (business) ,Cancer ,Cancer och onkologi ,Precision medicine ,High-Throughput Nucleotide Sequencing ,Disease monitoring ,medicine.disease ,Minimal residual disease ,Transplantation ,Cancer and Oncology ,Immunotherapy ,Immune-seq - Abstract
Cancer is characterized by an extremely complex biological background, which hinders personalized therapeutic interventions. Precision medicine promises to overcome this obstacle through integrating information from different ‘subsystems’, including the host, the external environment, the tumor itself and the tumor micro-environment. Immunogenetics is an essential tool that allows dissecting both lymphoid cancer ontogeny at both a cell-intrinsic and a cell-extrinsic level, i.e. through characterizing micro-environmental interactions, with a view to precision medicine. This is particularly thanks to the introduction of powerful, high-throughput approaches i.e. next generation sequencing, which allow the comprehensive characterization of immune repertoires. Indeed, NGS immunogenetic analysis (Immune-seq) has emerged as key to both understanding cancer pathogenesis and improving the accuracy of clinical decision making in oncology. Immune-seq has applications in lymphoid malignancies, assisting in the diagnosis e.g. through differentiating from reactive conditions, as well as in disease monitoring through accurate assessment of minimal residual disease. Moreover, Immune-seq facilitates the study of T cell receptor clonal dynamics in critical clinical contexts, including transplantation as well as innovative immunotherapy for solid cancers. The clinical utility of Immune-seq represents the focus of the present contribution, where we highlight what can be achieved but also what must be addressed in order to maximally realize the promise of Immune-seq in precision medicine in cancer.
- Published
- 2022